SCHEMBL318939

SCHEMBL318939

CC(C)(O)c1cc(F)cc(F)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA9 Q16790 1/20 0.41
CES2 O00748 1/20 0.36
CES1 P23141 1/20 0.36
CHRM3 P20309 1/20 0.36
CYP11B2 P19099 5/20 0.36
CYP11B1 P15538 4/20 0.36
SLC6A3 Q01959 1/20 0.35
TNKS O95271 4/20 0.35
PARP1 P09874 4/20 0.35
TNKS2 Q9H2K2 4/20 0.35
PARP2 Q9UGN5 1/20 0.35
PARP3 Q9Y6F1 1/20 0.35
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
PTGS1 P23219 1/20 0.32
PTGS2 P35354 1/20 0.32
GABRA1 P14867 1/20 0.31
GABRB2 P47870 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24030011 0.94 MEN1 (0.37) CA12CA1CA9CES2CES1
SCHEMBL765057 0.85 PGK1 (0.36) CYP11B2CYP11B1TNKSPARP1TNKS2
SCHEMBL15123029 0.84 CYP11B1 (0.32) CYP11B2CYP11B1TNKSPARP1TNKS2
SCHEMBL31075912 0.84 NOTUM (0.33) CYP11B2CYP11B1TNKSPARP1TNKS2
SCHEMBL25485523 0.83 CA12 (0.41) CA12CA1CA9CES2CES1
SCHEMBL27793273 0.82 CA1 (0.41) CA1CYP11B2CYP11B1PTGS1HSD11B1
SCHEMBL10203676 0.80 SLC6A3 (0.33) CYP11B2CYP11B1SLC6A3TNKSPARP1
SCHEMBL19552665 0.80 MGLL (0.37) CYP11B2CYP11B1TNKSPARP1TNKS2
SCHEMBL31322665 0.80 CYP4F2 (0.43) CHRM3CYP11B2CYP11B1TNKSPARP1
SCHEMBL24526539 0.79 HCAR1 (0.52) CA12CA1CA9CES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4186897-A1 PYRIDINECARBOXAMIDE COMPOUND USEFUL AS PIM KINASE INHIBITOR Incyte Holdings Corporation (US) 2023-05-31 EP disclosed
EP-4186897-A1 PYRIDINECARBOXAMIDE COMPOUND USEFUL AS PIM KINASE INHIBITOR Incyte Holdings Corporation (US) 2023-05-31 EP disclosed
EP-3670506-B1 THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS INCYTE HOLDINGS CORP (US) 2023-01-04 EP disclosed
EP-3670506-B1 THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS INCYTE HOLDINGS CORP (US) 2023-01-04 EP disclosed
CN-108715590-B Thiazolecarboxamide and picolinamide compounds useful as PIM kinase inhibitors 因赛特公司 2022-03-08 CN disclosed
US-11229631-B2 Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors INCYTE CORPORATION (US) 2022-01-25 US disclosed
US-11229631-B2 Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors INCYTE CORPORATION (US) 2022-01-25 US disclosed
US-20200405702-A1 THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS INCYTE CORPORATION 2020-12-31 US disclosed
US-20200405702-A1 THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS INCYTE CORPORATION 2020-12-31 US disclosed
US-10828290-B2 Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors INCYTE CORPORATION (US) 2020-11-10 US disclosed
WO-2012004217-A1 CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS NOVARTIS AG (CH) 2012-01-12 WO disclosed
EP-1995241-B1 Inhibitors of ion channels ICAGEN INC (US) 2010-03-17 EP disclosed
EP-1995241-B1 Inhibitors of ion channels ICAGEN INC (US) 2010-03-17 EP disclosed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 US disclosed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 US disclosed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 US disclosed
EP-1995241-A1 Inhibitors of ion channels ICAgen, Incorporated (US) 2008-11-26 EP disclosed
EP-1995241-A1 Inhibitors of ion channels ICAgen, Incorporated (US) 2008-11-26 EP disclosed
WO-2008118758-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (GB) 2008-10-02 WO disclosed
WO-2008118758-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (GB) 2008-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200405702-A1 THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS PIM2, PIM1, PIM3 CA12 3308/4885CA1 3982/4885CA9 2196/4885
US-11229631-B2 Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors PIM2, PIM1, PIM3 CA12 3308/4885CA1 3982/4885CA9 2196/4885
US-20090143358-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPV5, TRPA1 CA12 2666/4885CA1 1063/4885CA9 1552/4885
US-10828290-B2 Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors PIM2, PIM1, PIM3 CA12 3308/4885CA1 3982/4885CA9 2196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.